Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves Medical Device For Monthly Injection Of PCSK9 Inhibitor

XTALKS VITALS NEWS

Cholesterol

High levels of LDL cholesterol in the blood has been associated with a higher risk of cardiovascular disease.

Tweetables from this article:

Tweet: Repatha is a monoclonal antibody PCSK9 inhibitor http://ctt.ec/G26yL+Repatha is a monoclonal antibody PCSK9 inhibitor.

Tweet: High levels of LDL cholesterol associated with cardiovascular disease http://ctt.ec/dfqbS+High levels of LDL cholesterol associated with cardiovascular disease.

Share this!

July 12, 2016 | by Sarah Massey, M.Sc.

The US Food and Drug Administration (FDA) has approved a new monthly, single dose medical device - called Pushtronex - for the infusion of the LDL cholesterol-lowering drug, Repatha. Marketed by Amgen, Repatha is a monoclonal antibody belonging to the PCSK9 inhibitor class of drugs.

The Pushtronex hands-free medical device consists of a pre-filled cartridge containing 420 mg of Repatha. Despite the availability of other PCSK9 inhibitors, Amgen is the first company to offer the biologic as a once-monthly treatment.

“The Pushtronex system exemplifies Amgen's continued innovation and commitment to patients,” said Dr. Sean E. Harper, executive vice president of Research and Development at Amgen. “Repatha is the only PCSK9 inhibitor with an approved monthly dose, and now the only one with a monthly single-dose administration. The FDA approval of the Pushtronex system offers another delivery option to patients who need the additional LDL cholesterol lowering that Repatha can provide.”



Repatha is approved in the US to treat LDL cholesterol-associated conditions, including heterozygous familial hypercholesterolemia (HeFH), clinical atherosclerotic cardiovascular disease (ASCVD) and homozygous familial hypercholesterolemia (HoFH). In some indications, it is used in combination with other cholesterol-lowering therapies, such as statins, and in conjunction with changes in diet.

Based on SmartDose Technology, Amgen developed the single-use medical device in collaboration with West Pharmaceutical Services. By offering an additional dosing option, patients are able to perform moderate physical tasks such as walking, while receiving their dose of Repatha subcutaneously.

According to Amgen, the U.S. Wholesale Acquisition Cost (WAC) of Repatha is $14,100 annually, however the company anticipates the patient and payer costs to be significantly lower. Amgen expects the Pushtronex system will be available to US patients as early as August.

High levels of LDL cholesterol in the blood has been associated with a higher risk of cardiovascular disease. Approximately 11 million people in the US have ASCVD and/or familial hypercholesterolemia (FH), which is not adequately controlled using traditional statin drugs or other cholesterol-lowering treatments alone.

Amgen’s Repatha is currently approved in 43 countries, including major markets in the US, Japan and Canada. While applications in other countries are pending, the drug is also available in all 28 member states in the EU.


Keywords: FDA, Medical Device, PCSK9 Inhibitor


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News


CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.